Atherosclerotic renal artery stenosis

First published June 2007, updated December 2021

Key points:

• Atherosclerotic renovascular disease accounts for more than 90 per cent of renal artery stenosis in the western population.
• ARAS is largely a disease of the ageing and is commonly associated with hypertension and renal dysfunction.
• It should be suspected in patients presenting with renal dysfunction and hypertension or a background of atheromatous disease elsewhere.
• Blood pressure can be controlled successfully in more than 90 per cent of patients with ARAS, but careful monitoring of renal function is necessary particularly in patients with significant bilateral renal artery stenosis and renal artery stenosis affecting the solitary kidney.
• Revascularisation unfortunately does not lead to predictable improvement in blood pressure or renal function in patients with ARAS.
• Further well-designed large-scale randomised trials are essential to determine the subgroup of patients who benefit from revascularisation.

Atherosclerotic renovascular disease accounts for more than 90 per cent of renal artery stenosis in the western population, with fibromuscular dysplasia accounting for the remainder¹. In the Indian subcontinent and the far-east, Takayasu’s arteritis is responsible for up to 60 per cent of cases with renal artery stenosis². Atherosclerotic renal artery stenosis (ARAS) is largely a disease of the elderly and is commonly associated with hypertension and renal dysfunction (Table 1). However, it is being increasingly diagnosed in the younger age groups because of improvement in the screening for renal failure and also easy access to sensitive non-invasive imaging techniques.

Prevalence

Atherosclerotic renovascular disease is common in the elderly. Incidental renal artery stenosis of more than 50 per cent was found in 40 per cent of patients older than 75 years at post mortem³. The prevalence and incidence of atherosclerotic renal artery disease in patients older than 67 years based on Medicare data from the US was 0.5 per cent and 3.7 per 1,000 patient years respectively⁴. The prevalence of ARAS is higher in those with coronary atherosclerosis and peripheral vascular disease. Incidental 50 and 75 per cent stenosis was found in 9.1 per cent and 4.8 per cent respectively in a review of 4,000 patients who underwent DR ASHIT KUMAR SHETTY abdominal aortography following coronary angiogram⁵. The presence of 75 per cent stenosis was associated with a significant decrease in survival (57 per cent versus 89 per cent adjusted HR 2.0 for mortality). Also 11 to 42 per cent of patients with peripheral vascular disease were noted to have up to 50 per cent narrowing in at least one renal artery in other studies⁶ . In addition, atherosclerotic renovascular disease may be responsible for five to 22 per cent of patients with advanced renal failure who are over the age of 50 years⁷. Data from the USRDS database between 1991–1997 shows that renovascular disease related end stage renal disease (ESRD) is increasingly faster than other-cause ESRD with an annual increase of 12.4 per cent per year⁸.

Clinical features

Atherosclerotic renovascular disease is found in two to five per cent of all cases of hypertension and 90 per cent of patients with atherosclerotic renovascular disease are hypertensives. The cooperative study of renovascular hypertension was established in order to define the clinical characteristics differentiating atherosclerotic renovascular disease from essential hypertension⁸.

The urinary sediment in renovascular disease is usually bland with a few red cells and mild to moderate proteinuria. Renal impairment occurs due to a combination of the effects of severe hypertension on the intrarenal circulation and the chronic hypo-perfusion that occurs when the systemic blood pressure drops as a result of antihypertensive therapy.

Progression of renal artery lesions Atherosclerotic lesions progress at varying rates. Studies where serial arteriography or Doppler ultrasonography were performed suggested that progressive stenosis occurs in 11 per cent of arteries with atherosclerotic lesions at 2.6 years⁹ and in 30 to 60 per cent within four to seven years¹⁰ despite adequate control of the blood pressure. In a prospective study, serial duplex Doppler ultrasonography was performed on 295 kidneys in 170 patients with ARAS, almost all of whom were on antihypertensive therapy¹¹.

The cumulative incidence of any progression at three years was 28 per cent among arteries with an initial stenosis that was less than 60 per cent and 49 per cent among arteries with more than 60 per cent stenosis at entry. However, complete occlusion occurred in only nine renal arteries (three per cent), seven of which were initially classified as having >60 per cent stenosis. Thus, significant stenosis carries a higher risk of progression and long-term loss of renal mass and function.

Diagnosis

Atherosclerotic renovascular disease should be suspected in patients presenting with renal dysfunction and hypertension on a background of atheromatous disease elsewhere.

Investigations

Investigations in the workup of ARAS can be divided in to those that demonstrate the presence and degree of stenosis and functional studies that attempt to identify the response to revascularisation.

Table 1. Types of renal artery stenosis

Treatment of atherosclerotic renovascular disease

The management of ARAS has suffered from the lack of large well-designed trials comparing conservative medical management with interventional procedures. The available data on the natural history of the disease favours conservative management in patients with stable renal failure and well controlled hypertension.

The difficulty in predicting a beneficial result and the concerns that the lesions might progress quicker following an angioplasty+/- stent also makes conservative management a safer option in patients who are stable.

With some suspect vessels, the rate of restenosis after stenting has been as high as 18 per cent per year, a higher rate than observed with untouched suspect vessels. As with coronary artery disease, this phenomenon may be due to thrombosis and/or accelerated neointimal formation resulting from vascular injury.

Table 2. Clinical features suggestive of renovascular disease

Medical management

General renal and cardiovascular outcomes with medical therapy alone were best studied in a retrospective report of 68 patients with high-grade (>70 per cent) ARAS who did not undergo revascularisation¹². From this, 21 patients had bilateral stenosis or stenosis in a single kidney. Among these 21 patients (average age 75 years), the average serum creatinine concentration was 1.6mg/ dL (141µmol/L) compared to 1.3mg/dL (115µmol/ L) for those with unilateral disease. At three-year follow-up, the mean blood pressure was 160/81mmHg.

An increase of at least 50 per cent in the serum creatinine concentration was observed in four of the 21 patients (19 per cent), two of whom progressed to end-stage disease. The remaining 17 patients had stable renal function. However, the mortality rate was 43 per cent, due most commonly to myocardial infarction or heart failure. The outcomes were better in patients with unilateral disease with 13 per cent showing a decline in their renal function and a mortality rate of 21 per cent.

The corner stones of medical treatment are optimal blood pressure control with agents including ACE inhibitors, risk factor management including cessation of smoking, glycaemic control in diabetics, aspirin and lipid management with statins. The use of ACE inhibition in renal artery stenosis can have a beneficial effect on the unaffected kidney in unilateral disease. In bilateral disease, ACE inhibitors have a predictable deleterious effect on the GFR specially when used in conjunction with diuretics, but this effect is usually reversible. Persistent severe stenosis appears to carry the risk of long-term loss of renal mass and whether this effect is seen more with ACE inhibitors is debatable.

Blood pressure can be controlled successfully in more than 90 per cent of patients with ARAS, but careful monitoring of renal function is necessary particularly in patients with significant bilateral renal artery stenosis and renal artery stenosis affecting the solitary kidney.

Revascularisation

The revascularisation procedure of choice in most centres is percutaneous angioplasty with stent implantation. This recommendation is based upon clinical experience and the success of stenting in coronary lesions. Surgical revascularisation is performed if angioplasty fails or concomitant aortic surgery is required, as for an abdominal aortic aneurysm or aortic occlusive disease.

Angioplasty has been primarily used for nonostial lesions, as these are most amenable to this procedure. Previous published reports suggest a 65 to 70 per cent initial success rate followed by improvement in renal function in 35 to 50 per cent and stabilisation of renal functions in 12 to 50 per cent of patients^13,14. In one study, a 20 per cent or greater fall in the plasma creatinine concentration was noted in 10 of 27 patients with moderate renal insufficiency (while two were worse after the procedure) and in four of 16 (while four were worse) with more advanced disease (plasma creatinine concentration above 3.4mg/dL or 300µmol/L)¹³. Serious complications (renal artery occlusion or perforation, atheroemboli, or embolic stroke) were noted in 10 per cent of cases. The long-term benefit of angioplasty alone is unclear.

In an attempt to improve the efficacy of angioplasty in ostial lesions and to diminish the incidence of restenosis, balloon-expandable intravascular stents have been placed at the time of angioplasty. Stent placement is associated with a lower restenosis rate than angioplasty alone (17 versus 26 per cent in one review of 14 studies including >600 patients)¹⁵. With respect to renal function, angioplasty with stent placement can be beneficial as shown in a number of small descriptive non-randomised studies^16,17,18.

Table 3. Investigations that show the presence and degree of stenosis

Table 4. Investigations for identifying the response to revascularisation

However small randomised trials^19,20,21 have so far demonstrated modest improvements in blood pressure control and no improvement in renal function. A randomised trial comparing stenting versus angioplasty²² showed better arterial patency with stenting without any significant improvement in renal function. Similarly, a non-randomised study comparing revascularisation with medical treatment failed to show a significant difference in renal function or mortality between the two groups at five years²³.

Identification of patients who respond to revascularisation is difficult. A high resistive index on duplex Doppler ultrasonography may indicate intrarenal disease and therefore predict poor outcome²⁴. Revascularisation appears to work better when there is an acute decline in renal function. Revascularisation in kidneys, which measure less than 8cm, and in patients with advanced chronic renal failure is less likely to result in improvement in renal functions. However, it can sometimes delay the need for renal replacement in people with advanced renal failure²⁵.

With the current available evidence; the indications for revascularisation in clinical practice are:

• Recurrent flash pulmonary oedema with
• 60 per cent stenosis
• Significant renal artery stenosis with severe hypertension resistant to maximal medical therapy
• Inability to maintain renal function as systemic blood pressure drops
• Deteriorating renal functions in patients who cannot be taken off ACE inhibitors
• Unexplained progressive renal failure

Conclusion

Atherosclerotic renovascular disease accounts for the majority of renal artery stenosis cases in the western population. There is little controversy regarding the management of fibromuscular dysplasia, which is treated by percutaneous transluminal renal angioplasty. Revascularisation unfortunately does not lead to predictable improvements in blood pressure or renal function in patients with atherosclerotic renovascular disease. Further well-designed large-scale randomised trials are essential to determine the subgroup of patients who benefit from revascularisation and compare medical treatment versus revascularisation. Two ongoing European trials (ASTRAL and STAR) and one American trial may be able to throw some light on this issue.

References

1. Ching MC, Janet H, Kalra PA. Dilemmas in the management of Atherosclerotic renal artery stenosis. British Medical Bulletin 2005; 73–74: 35–55
2. Jain S, Kumari S, Ganguly NK, Sharma BK. Current status of takayasu arteritis in India. Int.J Cardiol Int.J Cardiol 1996; 54: S95–100
3. Schwartz CJ, White TA. Stenosis of the renal artery on unselected necropsy study. BMJ 1964; 2: 1415–21
4. Kalra PA, Guo H, Kausz AT, et al. Kidney Int Kidney Int 2005; 68(1): 293–301
5. Conlon PJ, Little MA, Pieper K, et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int Kidney Int 2001; 60(4): 1490–7
6. Leertouwer TC, Pattynama PM, van den Berg-Huysmans. AIncidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int Kidney Int 2001; 59(4): 1480–3
7. Van Ampting JM, Penne EL, Beek FJ. Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18(6): 1147–51
8. Fatica RA, Port FK, Young EW. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001; 37(6): 1184–90
9. Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 1998; 136: 913
10. Pohl MA, Novick AC. Natural history of atherosclerotic and fi brous renal artery disease: clinical implications. Am J Kidney Dis 1985; 5(4): A120– 30
11. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. Circulation 1998; 98(25): 2866–72
12. Chabova V, Schirger A, Stanson AW. Outcomes of atherosclerotic renal artery stenosis managed without revascularisation. Mayo Clin Proc 2000; 75(5): 437–44.
13. Pattison JM, Reidy JF, Rafferty MJ, et al. Percutaneous transluminal renal angioplasty in patients with renal failure. QJ Med 1992; 85(307-308): 883–8
14. Connolly JO, Higgins RM, Walters HL, et al. Presentation, clinical features and outcome in different patterns of atherosclerotic renovascular disease. QJM 1994; 87(7): 413–21
15. Leertouwer TC, Gussenhoven EJ, Bosch JL, et al. Stent placement for renal arterial stenosis: where do we stand? A meta-analysis. Radiology 2000; 216(1): 78–85
16. Watson PS, Hadjipetrou P, Cox SV, et al. Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease. Circulation 2000; 102(14): 1671–7
17. Isles CG, Robertson S, Hill D. Management of renovascular disease: a review of renal artery stenting in ten studies. QJM 1999; 92(3): 159–67
18. Harden PN, MacLeod MJ, Rodger RS, et al. Effect of renal-artery stenting on progression of renovascular renal failure. Lancet 1997; 349(9059): 1133–6
19. Van Jarsveld BC, Krijneen P, Peitermen H, et al. The effect of balloon angioplasty on hypertension in Atherosclerotic renal artery stenosis. NEJM 342: 1007–14
20. Ploin PF, Chatelliar G,Dorne B, et al. Blood pressure outcome of 1angioplasty in atherosclerotic renal artery stenosis. Hypertension 1998; 31: 823–9
21. Websterr J, Marshall F, Abdella M, et al. Randomised comparison of percutaneous angioplasty versus continued medical therapy for hypertensive patients with atherosclerotic renal artery stenosis. J Hum Hypertension 1998; 12: 329–35
22. Vaqn den Ven PJG,Kaoter R,Beutler JJ, et al. Arterial stenting and ballon angioplasty in ostial Atherosclerotic renovascular disease-A randomised trial. Lancet 1999; 358: 282–86
23. Losito A, Errico R, Santirosi P, et al. Long-term follow-up of atherosclerotic renovascular disease. Benefi cial effect of ACE inhibition. Nephrol Dial Transplant 2005; 20(8): 1604–9.
24. Radermacher J, Chavan A, Bleck J. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344(6): 410–7
25. Korsakas S, Mohaupt MG, Dinkel HP. Delay of dialysis in end-stage renal failure: prospective study on percutaneous renal artery interventions. Kidney Int 2004; 65(1): 251-8